Impact of Tacrolimus Intra‐Patient Variability on Toxicity Development Among Lung Transplant Recipients
Basic & Clinical Pharmacology & Toxicology · 2026-05 · 138 (5)
DOI: 10.1111/bcpt.70229 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 26.03.2026. Verfasst von Rita Nogueiras-Álvarez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Osakidetza-Basque Health Service, Galdakao-Usansolo University Hospital, Galdakao, Bizkaia, Spain. Hauptthemen laut MEDLINE: Tacrolimus, Lung Transplantation, Immunosuppressive Agents, Graft Rejection. Die Arbeit nennt 50 Literaturangaben.
Abstract (Originalsprache)
Immunosuppressive treatment helps to reduce the risk of rejection after transplantation. However, it is important to be aware of the potential toxicities that can develop after this therapy initiation. Tacrolimus is currently the calcineurin inhibitor of choice in the post‐transplantation immunosuppressive therapy, and its intra‐patient variability (Tac‐IPV) has been proposed in recent years as a useful biomarker in post‐transplant outcomes. We performed an observational retrospective study in 195 lung transplant recipients to determine the potential impact of Tac‐IPV as a biomarker in the development of cardiovascular toxicities and renal impairment in the post‐transplantation evolution. Different Tac‐IPV calculation measurements were shown to be statistically associated with the development of arterial hypertension de novo in the univariate analysis: the standard deviation ( p = 0.016 for tacrolimus C min values; p = 0.022 for tacrolimus dose‐adjusted values); the coefficient of variation ( p = 0.021 for C min ; p = 0.031 for dose‐adjusted values); and the mean absolute deviation (MAD) ( p = 0.043 for C min ; p = 0.033 for dose‐adjusted values). Those patients with a MAD ≥ 16.47% had a higher risk of renal impairment ( p = 0.045). In our study, different Tac‐IPV measures were associated with arterial hypertension in lung transplantation follow‐up. Patients with a high Tac‐IPV, using the MAD as a measurement, showed a higher risk for renal impairment. No other statistically significant associations were found for the other studied events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Osakidetza-Basque Health Service, Galdakao-Usansolo University Hospital, Galdakao, Bizkaia, Spain.
- Respiratory Department, Marqués de Valdecilla University Hospital, Santander, Cantabria, Spain.
- IDIVAL (Instituto de Investigación Sanitaria Valdecilla), Santander, Cantabria, Spain.
- University of Cantabria, Santander, Cantabria, Spain.
- Clinical Pharmacology Department, Marqués de Valdecilla University Hospital, Santander, Cantabria, Spain.
ORCID-Profile: Rita Nogueiras-Álvarez, Víctor Manuel Mora-Cuesta, José Manuel Cifrián-Martínez, María Del Mar García-Saiz
Zitieren
APA
Nogueiras-Álvarez, R., Mora-Cuesta, V. M., Cifrián-Martínez, J. M., & García-Saiz, M. D. M. (2026). Impact of Tacrolimus Intra‐Patient Variability on Toxicity Development Among Lung Transplant Recipients. Basic & Clinical Pharmacology & Toxicology, 138(5). https://doi.org/10.1111/bcpt.70229
Vancouver
Nogueiras-Álvarez R, Mora-Cuesta VM, Cifrián-Martínez JM, García-Saiz MDM. Impact of Tacrolimus Intra‐Patient Variability on Toxicity Development Among Lung Transplant Recipients. Basic & Clinical Pharmacology & Toxicology. 2026;138(5). doi:10.1111/bcpt.70229
BibTeX
@article{Nogueiraslvarez2026,
author = {Nogueiras-Álvarez, Rita and Mora-Cuesta, Víctor Manuel and Cifrián-Martínez, José Manuel and García-Saiz, María Del Mar},
title = {Impact of Tacrolimus Intra‐Patient Variability on Toxicity Development Among Lung Transplant Recipients},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
volume = {138},
number = {5},
doi = {10.1111/bcpt.70229}
}
EUVIMED